Valuation Scholar Rock Holding Corporation
Stocks
SRRK
US80706P1030
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 51.73 USD | -4.27% |
|
-7.67% | +17.43% |
| 07-07 | Weight-loss drug developers line up to tap lucrative market as competition heats up | RE |
| 06-11 | Weight-loss drug developers line up to tap lucrative market as competition heats up | RE |
Company Valuation: Scholar Rock Holding Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 872.1 | 467.6 | 1,356 | 4,046 | 4,493 | 6,476 | - | - |
| Change | - | -46.39% | 190.08% | 198.32% | 11.06% | 44.11% | - | - |
| Enterprise Value (EV) 1 | 709.3 | 414 | 1,304 | 3,918 | 4,270 | 6,173 | 6,120 | 6,183 |
| Change | - | -41.63% | 215.07% | 200.38% | 8.97% | 44.59% | -0.87% | 1.03% |
| P/E | -6.92x | -4x | -9.45x | -17.5x | -13.4x | -17x | -21.2x | -35x |
| PBR | 5.3x | 2.07x | 6.96x | 11x | 20.6x | 26.2x | 25.6x | 31.7x |
| PEG | - | 0.1x | 0.8x | -0.7x | -0.4x | 5.02x | 1.1x | 0.9x |
| Capitalization / Revenue | 46.3x | 14.1x | - | - | - | 994x | 43.3x | 18.5x |
| EV / Revenue | 37.7x | 12.5x | - | - | - | 948x | 40.9x | 17.7x |
| EV / EBITDA | -5.57x | - | - | - | -11.1x | -14.5x | -20.9x | -63.3x |
| EV / EBIT | -5.46x | -3.08x | -7.62x | -15.5x | -11.1x | -14.3x | -18.1x | -33.4x |
| EV / FCF | -5.37x | -3.1x | -8.98x | -19.5x | -14.2x | -19x | -27.5x | -69.3x |
| FCF Yield | -18.6% | -32.3% | -11.1% | -5.13% | -7.04% | -5.27% | -3.64% | -1.44% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -3.59 | -2.26 | -1.99 | -2.47 | -3.29 | -3.179 | -2.552 | -1.546 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 18.82 | 33.19 | - | - | - | 6.512 | 149.5 | 350.1 |
| EBITDA 1 | -127.3 | - | - | - | -383 | -426.8 | -292.4 | -97.64 |
| EBIT 1 | -129.9 | -134.4 | -171.3 | -252.1 | -384.6 | -430.4 | -337.6 | -185.1 |
| Net income 1 | -131.8 | -134.5 | -165.8 | -246.3 | -377.9 | -409.7 | -356.3 | -209.9 |
| Net Debt 1 | -162.8 | -53.53 | -51.84 | -127.7 | -223.8 | -302.1 | -355.6 | -292.4 |
| Reference price 2 | 24.84 | 9.05 | 18.80 | 43.22 | 44.05 | 54.04 | 54.04 | 54.04 |
| Nbr of stocks (in thousands) | 35,108 | 51,663 | 72,143 | 93,615 | 102,007 | 119,828 | - | - |
| Announcement Date | 7/3/22 | 7/3/23 | 19/3/24 | 27/2/25 | 3/3/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -17x | 948.03x | -14.47x | -.--% | 6.48B | |
| 21.75x | 6.73x | 14.72x | 1.46% | 57.82B | |
| 32.16x | 8.12x | 25.19x | 0.06% | 53.71B | |
| -43.06x | 13.69x | -40.15x | -.--% | 23.8B | |
| -18.33x | 4.37x | -7.66x | -.--% | 23.26B | |
| 25.89x | 5.11x | 13.48x | -.--% | 20.7B | |
| 24.77x | 4.84x | 15.78x | -.--% | 17.81B | |
| 50.68x | 20.65x | 53.17x | 0.07% | 16.9B | |
| -560.54x | 39.3x | -4381.59x | -.--% | 16.36B | |
| 17.45x | 5.07x | 11.8x | -.--% | 13.96B | |
| Average | -46.62x | 105.59x | -430.97x | 0.16% | 25.08B | |
| Weighted average by Cap. | -22.60x | 34.47x | -275.43x | 0.35% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- SRRK Stock
- Valuation Scholar Rock Holding Corporation
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
